Transcranial sonography in the prognosis of drug-induced parkinsonism
Objective: We investigated the substantia nigra (SN) echogenicity in drug-induced parkinsonism (DIP), Parkinson's disease (PD), and healthy controls. A subgroup analysis of DIP by clinical…Effects of the administration of levodopa on postural control under visual tasks
Objective: We tested if the administration of levodopa leads the patients with Parkinson’s disease to sway significantly more than the controls, especially under challenging visual…Effect of Deutetrabenazine on QTcF Interval in the AIM-TD Study: a 12-Week, Phase III, Randomized, Double-Blind, Placebo-Controlled Study
Objective: To evaluate the effect of deutetrabenazine (DTB) on QT interval prolongation in patients with tardive dyskinesia (TD) in the AIM-TD study. Background: TD is…Off-Target Implications of Nurr1 Agonist Therapy in Parkinson’s disease
Objective: To examine the impact of Nurr1 agonists on regulation of striatal Nurr1 and levodopa (LD)-induced dyskinesias (LIDs) in a rat model of Parkinson’s disease…Low Incidence of Extrapyramidal Symptoms in Subjects with Tardive Dyskinesia Receiving Long-Term Valbenazine (NBI-98854) Treatment
Objective: To assess the emergence of extrapyramidal symptoms (EPS) such as akathisia and parkinsonism in adults with a diagnosis of schizophrenia/schizoaffective disorder or mood disorder…Prevalence of Parkinson’s disease and Drug-induced Parkinsonism from National Health Insurance Service Claims Data (NHISCD)
Objective: To evaluate the prevalence and characteristics of of drug induced parkinsonism Background: Drug induced parkinsonism (DIP) is a clinically important disease because it can…Drug-induced movement disorders: not a typical problem
Objective: To characterize patients with neuroleptic drug-induced movement disorders (DIMD) referred to a single academic center Movement Disorders clinic, their causative medications and the indications…Long-Term Safety of Deutetrabenazine for the Treatment of Tardive Dyskinesia: Results From an Open-Label, Long-Term Study
Objective: To evaluate the long-term safety/tolerability of deutetrabenazine (DTB) in patients with tardive dyskinesia (TD). Week 54 open-label results are reported in this interim analysis.…Effect of Deutetrabenazine on Quality of Life in Patients With Tardive Dyskinesia in AIM-TD, a 12-Week Double-Blind, Placebo-Controlled Study
Objective: To assess the effect of deutetrabenazine (DTB) on quality of life (QoL) of patients with tardive dyskinesia (TD) as measured by the modified Craniocervical…Improvements in Clinical Global Impression of Change With Deutetrabenazine Treatment in Tardive Dyskinesia From the ARM-TD and AIM-TD Studies
Objective: To evaluate the efficacy of deutetrabenazine (DTB), as measured by the Clinical Global Impression of Change (CGIC), in patients with tardive dyskinesia (TD) from…
Abstracts from the International Congress of Parkinson’s and Movement Disorders.